Abstract library

1580 results for "metastatic type one gastric carcinoid".
#2745 Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids
Introduction: Lung carcinoids (LCs) are rare and slow growing primary lung neuroendocrine tumors. The WHO classify LCs into atypical and typical carcinoids. Recent studies have shown that the reproducibility of LCs classification and its prognostic efficacy have high interobserver variability
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Saurabh V Laddha
#2815 Unexpected High Rate of Metastases in Type 1 Gastric Neuroendocrine Neoplasia
Introduction: Gastric neuroendocrine neoplasms (gNEN) represent about 7.5% of gastroenteropancreatic NEN (gepNEN), classified in: type 1 (70-80%), related to autoimmune gastritis, type 2 (5%), related to Zollinger-Ellison syndrome in multiple endocrine neoplasia 1 and type 3 (15-20%), in absence of hypergastrinemia or mucosal atrophy.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Filomena Bottiglieri
#2683 Clinicopathological Features and Prognostic Analysis of 227 Cases with Well-Differentiated Gastric Neuroendocrine Tumors
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a group of rare tumors with a strong heterogeneity, subdivided as well-differentiated neuroendocrine tumors (NETs, type 1-3 g-NETs) and poorly-differentiated neuroendocrine carcinoma(NECs). WHO classification(2019) for digestive system tumours has carried out a new classification and grading criteria for NENs of the gastrointestinal tract recently, there is very few relevant clinical data based on this new classification, especially for gastric NETs(g-NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Yuanliang Li
Authors: Li Y, Tan H, Jie C, Jie L, ...
#2804 Claudin-18 Is a Sensitive and a Specific Marker for Gastric Neuroendocrine Tumors
Introduction: Antibody-based cancer therapies are emerging as promising therapeutics in oncology, including one in clinical trials that targets claudin-18, a protein expressed in normal gastric epithelium and some gastric adenocarcinoma. We currently have no markers for gastric well-differentiated neuroendocrine tumors (NETs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Housestaff Mary Wong
Authors: Wong M, Huynh C, Kim S, Dhall D, ...
#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours
Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Anguraj Sadanandam
#2711 Gastric Neuroendocrine Neoplasms: Clinical Management and Outcomes in a Cohort of 54 Patients
Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10-20% can be type 3 or type 4 Gastric NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Alexandra Victor
Authors: Victor A, Ramage J, Cope J, Maclean R, ...
#3015 Biopsy Specimen Diagnosis in Pulmonary Carcinoids, A Shot in the Dark
Introduction: Pulmonary carcinoids (PCs) are rare well-differentiated neuroendocrine tumors, which can be separated into typical carcinoid (TC) and atypical carcinoid (AC). Advised treatment for local carcinoid disease is surgical resection using lobectomy, while parenchymal saving strategies such as sub-lobar or endobronchial resection might be considered for TC. In general, pre-operative diagnosis using a (transbronchial/transthoracic) biopsy sample is performed to demonstrate malignancy. However, TC and AC classification can solely be performed on surgical resection specimens, which may challenge pre-operative treatment decisions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: Drs Laura Moonen
#3020 Outcomes Following Surgical Management of Pulmonary Carcinoids – A Tertiary Center Experience
Introduction: Pulmonary carcinoids are a rare type of malignant lung tumour. Surgery forms the mainstay of management when operable. However, there is paucity of data on conservative management and effective follow-up strategies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Dr Md Deloar Hoshen
#2862 Concurrent Metastatic Pulmonary Neuroendocrine Tumor and Pituitary Macroadenoma
Introduction: The coexistence of a sellar mass in a patient with a neuroendocrine tumor, while rare, can paint the clinical picture of either a genetic syndrome, most notably multiple endocrine neoplasia syndrome type 1(MEN1) or pituitary metastasis recently more frequent probably due to the longer survival of cancer patients.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD, PhD, Lecture Carmen Sorina Martin
#190 Complete Remission in a Patient with Metastatic Type 1 Gastric Carcinoid (GCA1) Treated with a Long-acting Somatostatin Analogue
Introduction: Surgery is the treatment of choice for invasive and metastatic GCA1. Somatostatin analogues have been successfully used in GCA1 patients without signs of malignancy.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr merav Fraenkel